Blood p-tau217 levels signal cognitive impairment risk years before symptoms emerge
A six-cohort study indicates that elevated levels of the protein p-tau217 in the blood can predict cognitive impairment years before clinical symptoms appear. While the findings offer promise for future risk modeling, researchers note that the test is not yet ready for routine clinical screening.
Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Videos Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Videos Contact Meet the Team Advertise Search Become a Member Blood p-tau217 levels signal cognitive impairment risk years before symptoms emerge Download PDF Copy Add News Medical on Google as a preferred source By Hugo Francisco de Souza Reviewed by Susha Cheriyedath, M.Sc. Jul 16 2026 A six-cohort analysis links higher baseline p-tau217 to rising 5- and 10-year risks, bringing presymptomatic risk models closer while showing why routine screening is not yet ready.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in